Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES

Next Previous
Trial Profile

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Avipendekin pegol (Primary) ; Ivuxolimab (Primary) ; PD 360324 (Primary) ; Utomilumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Giant cell tumour of tendon sheath; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms JAVELIN Bladder Medley; JAVELIN Medley
  • Sponsors Pfizer

Most Recent Events

  • 12 Oct 2023 Results (n=40) assessing safety and efficacy of avelumab combined with utomilumab and PF-04518600 in patients with recurrent gynecologic malignancies, published in the Cancer.
  • 04 Jun 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
  • 04 May 2023 Status changed from active, no longer recruiting to discontinued. The study was terminated since there was no need for further safety or efficacy data to becollected. The participants having benefit from investigational treatments have been movedto a continuation study (NCT05059522)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top